Skip to main content
. 2012 Jul 11;2012(7):CD006534. doi: 10.1002/14651858.CD006534.pub2

NCT00993876.

Methods Randomised, open‐label trial.
Participants Patients with MDD according to DSM‐IV criteria.
Interventions Citalopram: 20‐30 mg/day.
Reboxetine: 4‐8 mg/day.
Outcomes Cognitive performance with respect to cognitive flexibility, memory and attention.
Notes